Argenx Reports Strong Vyvgart Sales Growth
The company saw a 54% increase in sales for its lead drug despite lower-than-expected quarterly operating profits.
Updated on Oct. 22, 2026 in Healthcare
Live Poll
Do you trust pharmaceutical companies that prioritize large acquisitions over maintaining stable operating margins?
Argenx reported $1.7 billion in Vyvgart sales for the third quarter of 2026, marking a 54% growth compared to the same period in 2025. However, the company posted a lower-than-anticipated quarterly operating profit of $486 million.
Why it matters
The dip in operating profit stems from acquisition-related costs following the company's $2.2 billion purchase of Forte Biosciences in August 2026. While patient demand for Vyvgart continues to expand, integrating new portfolio costs has impacted near-term margins.
Quarterly operating profit reached $486 million, falling short of the $565.82 million analyst consensus, while the operating margin settled at 28.2%. The firm expects combined research, selling, and administrative costs to reach $4 billion for full-year 2026.
The players
Argenx
A biotechnology company headquartered in Belgium and the Netherlands that specializes in immunology.
Forte Biosciences
A biotechnology firm that was acquired by Argenx to expand its clinical research portfolio.
The details
The performance was driven by an expansion in the number of patients receiving Vyvgart treatment. These financial results incorporate the portfolio and associated expenses from the acquisition of Forte Biosciences.
Timeline
August 2026: Argenx completed the acquisition of Forte Biosciences.
Q3 2026: Vyvgart sales reached $1.7 billion.
Full Year 2026: Total R&D and SG&A costs are projected at $4 billion.
Market Landscape
This financial report illustrates the broader industry trend of rapid corporate consolidation in the biotech sector. Argenx is prioritizing long-term portfolio growth through high-value acquisitions, a strategy that shifts market share while temporarily suppressing operational margins.
The increase in patient access suggests a stable or growing availability for those seeking Vyvgart treatment. Investors should note that the company's aggressive acquisition strategy is the primary factor influencing its current profit margins.
The takeaway
Companies undergoing major acquisitions often face short-term profit volatility as they integrate new operational costs into their financial structure. Investors and patients should monitor how quickly Argenx can scale its new assets to offset these significant expansion expenses.
Further reading
For broader insights on industry trends, visit the Healthcare section.
Live Poll
Do you trust pharmaceutical companies that prioritize large acquisitions over maintaining stable operating margins?
